Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Apr 27, 2026

Cantargia Announces Early Results from Trial of nadunolimab in MDS and AML

Apr 17, 2026

Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC

Apr 17, 2026

(R) Cantargia publishes Annual Report 2025

Apr 17, 2026

(R) Notice of annual general meeting in Cantargia AB (publ)

Mar 18, 2026

New preclinical data on anti-tumor effects of nadunolimab in metastatic colorectal cancer presented at the Keystone Cancer Immunotherapy conference

Mar 5, 2026

Cantargia to participate at Van Lanschot Kempen’s Life Sciences Conference

Feb 23, 2026

Cantargia to participate in TD Cowen’s Annual Healthcare Conference

Feb 20, 2026

(R) Cantargia publishes Full Year Report 2025

Feb 6, 2026

Invitation to the Presentation of Cantargia’s Annual Results for 2025

Jan 28, 2026

Cantargia to participate at Leerink Partners Global Healthcare Conference

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye